GlassScriptPhysician profile
Todd William Schlossman
NPI 1558773713
$1,332.38
in general payments reported to CMS, 2019-2025
22 companies · $262 in 2025
The $262 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $88.88 · 2022: $357 · 2023: $297 · 2024: $327 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $196.46 | 2021-2025 | Breztri, Fasenra, Tezspire |
| Mallinckrodt Hospital Products INC. | $193.80 | 2021-2022 | |
| Glaxosmithkline, LLC. | $111.91 | 2022-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Grifols USA, LLC | $94.05 | 2021-2025 | Prolastin-C Liquid |
| Insmed, INC. | $88.64 | 2022-2025 | Arikayce |
| Genzyme Corporation | $85.86 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.73 | 2022-2025 | Glassia |
| Actelion Pharmaceuticals US, INC. | $71.03 | 2024-2025 | Opsumit, Uptravi |
| Electromed, INC. | $50.92 | 2023-2025 | Smartvest |
| Merck Sharp & Dohme LLC | $50.72 | 2023-2024 | Winrevair, Zerbaxa, Recarbrio |
| Regeneron Healthcare Solutions, INC. | $37.52 | 2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.39 | 2024 | Ofev |
| Jazz Pharmaceuticals INC. | $32.88 | 2023 | |
| Harmony Biosciences LLC | $31.81 | 2022 | |
| Baxter Healthcare | $29.23 | 2023 | Hillrom - Life 2000 Ventilation System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $28.27 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Abbvie INC. | $25.39 | 2024 | |
| Verona Pharma, INC. | $24.47 | 2025 | Ohtuvayre |
| Edwards Lifesciences Corporation | $21.50 | 2023 | Hemosphere |
| Zoll Respicardia, INC. | $19.60 | 2025 | Remede System |
| Paratek Pharmaceuticals, INC. | $18.28 | 2023 | Nuzyra |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Schlossman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.